Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Primary Central Nervous System Lymphoma (PCNSL) Clinical Trial

Official title:
Phase II Maintenance Trial of Nivolumab for Newly Diagnosed PCNSL Patients With Persistent Circulating Tumor DNA in the CSF After Completion of Methotrexate-Based First-Line Induction Chemotherapy

Status Active, not recruiting

Clinical Trial Summary

The purpose of this additional part of the study is to test whether the study drug, nivolumab, is a safe treatment that will prevent participants' primary central nervous system lymphoma (PCNSL) from growing again (recurrence). Participants will be people with PCNSL who continue to have cell free tumor DNA (cfDNA) in their CSF despite completion of their first treatment (first-line treatment).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Primary Central Nervous System Lymphoma (PCNSL)

Clinical Trial Details

NCT number	NCT04401774
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	May 22, 2020
Completion date	May 22, 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04830137` - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies	Phase 1
Active, not recruiting	`NCT04253496` - Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)
Terminated	`NCT00710151` - Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors	N/A
Active, not recruiting	`NCT03703167` - Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)	Phase 1
Recruiting	`NCT04688151` - Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.	Phase 1
Recruiting	`NCT05131022` - A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies	Phase 1